Progressive epithelial ovarian carcinoma. Prognostic factors and clinical management.
Grønlund
Bo
B
Oncologic Clinic 5073, H:S Rigshospitalet, 2100 Copenhagen Ø, Denmark. bo.gronlund@dadlnet.dk
D000230:Adenocarcinoma / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology / Q000601:surgery; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D018394:CA-125 Antigen / Q000097:blood; D016190:Carboplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D018284:Cystadenocarcinoma, Serous / Q000175:diagnosis / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000601:surgery; D003718:Denmark / Q000453:epidemiology; D003952:Diagnostic Imaging; D018450:Disease Progression; D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000453:epidemiology; D010051:Ovarian Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality* / Q000473:pathology / Q000601:surgery; D017239:Paclitaxel / Q000008:administration & dosage; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D016019:Survival Analysis; D019772:Topotecan / Q000008:administration & dosage; D016896:Treatment Outcome
D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; D019772:Topotecan; D016190:Carboplatin; D017239:Paclitaxel